Breaking: HeartWare wins FDA nod for bridge-to-transplant heart pump

November 20, 2012 by MassDevice staff

HeartWare wins premarket approval for its flagship implantable left ventricular assist device as a bridge to transplant for heart failure patients.

HeartWare International logo

Framingham, Mass.-based cardiac device maker HeartWare International (NSDQ:HTWR) won FDA premarket approval for its HeartWare ventricular assist system as a bridge to heart transplantation.

The HeartWare system includes an implantable pump, external driver and power source that can be used either inside or outside of hospitals, the FDA noted.

Sign up to get our free newsletters delivered right to your inbox.

"For patients awaiting a donor heart, the HeartWare System provides a new treatment option," FDA Center for Devices & Radiological Health director Christy Foreman said in prepared remarks.

HeartWare representatives did not immediately return requests for comment.

Where other devices require pump components be placed in the abdomen, the HeartWare system fits in a small implant near the heart, which makes the device an option for smaller patients or those unable to have an implant in the abdomen, according to the federal watchdog agency.

"The FDA approved the HeartWare LVAD based on data from a clinical trial known as the ADVANCE trial," according to the agency notice. "The trial compared outcomes from 137 advanced heart failure participants using the HeartWare System with outcomes from similar patients followed by the Interagency Registry for Mechanically Assisted Circulatory Support."

This marks the 1st time the FDA has approved a left ventricular assist device based on clinical trials that relied on data as a control, the FDA noted.